Bayer Q1 2026 Deck: Litigation, Pipeline, Cash Flow

Bayer published its Q1 2026 earnings call slide deck on May 17, giving investors a structured look at the quarter's results and management's forward view. The deck, posted on Bayer's investor relations site, covers the three segments that define the investment case: Pharmaceuticals, Crop Science, and Consumer Health. Consumer Health**. For anyone tracking the stock, the slides are the primary source of detail until the full earnings transcript and 6-K filing arrive.

Bayer's Q1 2026 Deck: The Three Watchpoints

Bayer's quarterly presentations typically lead with group revenue and EBITDA before breaking down each division. The Q1 deck is the first full snapshot of 2026 performance. Investors should focus on three areas that have driven the stock's volatility over the past year.

Litigation Overhang and Cash Flow

Roundup litigation remains the dominant risk factor for Bayer's equity. The slide deck likely includes an update on the number of pending cases, settlement progress, and any new verdicts. Cash flow from operations is the second critical metric. Bayer has been using free cash flow to pay down debt and fund litigation reserves. A weak cash flow number in Q1 would raise questions about the dividend and the pace of deleveraging.

Pharma Pipeline Catalysts

Bayer's pharma division has been under pressure from generic competition for its top-selling drugs. The deck should highlight pipeline milestones for key assets such as elinzanetant (non-hormonal hot flash treatment) and treatment) and asundexian (Factor XIa inhibitor). Any regulatory updates or trial readouts in the slides could shift the medium-term revenue outlook. Investors will also watch for comments on the consumer health margin trajectory.